Novo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO
Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company that counts Novo Nordisk Foundation as one of its biggest investors, raised $301.5 million in an upsized US initial public offering that priced at the top of a marketed range.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.